소아 급성골수성백혈병에서 관해유도 요법 중 Posaconazole의 예방적 항진균 치료

키워드

참고문헌 (18)

1. Cuenca EM, "Update on the epidemiology and diagnosis of invasive fungal infection", Int J Antimicmb Agents, 32(2), pp.143~147 (2008)[DOI]
2. Berking S, "Antifungal prophylaxis in newly diagnosed AML patients adherence to guidelines and feasibility in a real life setting", Mycoses, 60(9), pp.600~606 (2017)[DOI]
3. Cornely OA, "Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia", N Engl J Med, 356(4), pp.348~359 (2007)[DOI]
4. Jung DS, "Switching from Posaconazole Suspension to Tablets Increases Serum Drug Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity", Antimicrob Agents Chemother, 58(11), pp.6993~6995 (2014)[DOI]
5. Durani U, "Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension", Antimicrob Agents Chemother, 59(8), pp.4914~4918 (2015)[DOI]
6. Bruggemann RJ, "Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents", Clin Infect Dis, 48(10), pp.1441~58 (2009)[DOI]
7. Krishna G, "Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers", Antimicrob Agents Chemother, 53(3), pp.958~966 (2009)[DOI]
8. Doring M, "Analysis of Posaconazole as Oral Antifungal Prophylaxis in Pediatric Patients Under 12 Years of Age Following Allogeneic Stem Cell Transplantation", BMC Infect Dis, 12, pp.263~ (2012)[DOI]
9. De PB, "Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer", Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC, Clin Infect Dis, pp.2008, 46(12)[DOI]
10. Lass-Florl C, "The changing face of epidemiology of invasive fungal disease in Europe", Mycoses, 52(3), pp.197~205 (2009)[DOI]
11. Kung HC, "Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients", Cancer Medicine, 3(3), pp.667~673 (2014)[DOI]
12. Cho SH, "Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations", Mycoses, 58(9), pp.565~571 (2015)[DOI]
13. Pagano L, "Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry", Br J Haematol, 170(3), pp.434~439 (2015)[DOI]
14. Muhlemann K, "Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies", Leukemia, 19(4), pp.545~550 (2005)[DOI]
15. Doring M, "Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation", J Cancer Res Clin Oncol, 143(7), pp.1281~1292 (2017)[DOI]
16. Gwee A, "Posaconazole: Promising but Problematic in Practice in Pediatric Patients", The Pediatr Infect Dis J, 34(6), pp.604~606 (2015)[DOI]
17. Gross BN, "Posaconazole Therapeutic Drug Monitoring in the Real-life Setting", Pharmacotherapy, 33(10), pp.1117~1125 (2013)[DOI]
18. Doring M, "Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia", Eur J Clin Microbiol Infect Dis, 34(6), pp.1189~1200 (2015)[DOI]

관련 논문AI추천